Robert Vescio is an Oncology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 208 publications with 10,406 citations (h-index 45); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Cedars-Sinai Medical Center 8700 Beverly Boulevard
C-2000
Los Angeles, CA 900481804
Telephone
310-423-1825Registry record last updated 30 Sept 2008.
Clinical trials
- Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
Sponsor: Cedars-Sinai Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202570 payments$72,865openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202516 payments$23,198openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year20256 payments$13,399openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.8%CD38-directed Cytolytic Antibody85.5%Daratumumab100%Part B, office-administered≥19 patientsThalidomide Analog1%Revlimid41%Lenalidomide33%Pomalyst26%Part D≥28 patients+ 3 more classes in this area
Anti-infectives
11.3%Human Immunoglobulin G11.1%Immune globulin100%Part B, office-administered≥14 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.1%Valacyclovir100%Part D≥27 patients+ 2 more classes in this area
Nervous system
0.9%Opioid Agonist0.4%Oxycodone Hcl35%Morphine Sulfate Er27%Fentanyl15%Tramadol Hcl12%Oxycodone-Acetaminophen12%Part D<11 patientsBenzodiazepine0.2%Clonazepam33%Diazepam28%Lorazepam24%Alprazolam16%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”